Alisha A. Alaimo Appointed SVP of Biogen’s US Therapeutic Operations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- First Financial to acquire Hickory Point Bank in $111.3M deal
- McKesson reports cybersecurity incident affecting its information systems
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- BioNTech ends colorectal cancer mRNA therapy trial early
Biogen (BIIB) PT Raised to $285 at UBS Following Strong 2Q
July 26, 2017 8:44 AM EDTUBS raised its price target on Biogen (NASDAQ: BIIB) to $285.00 (from $270.00) while maintaining a Neutral rating following the company's 2Q. BIIB recorded a $284M top-line beat. EPS also came in ahead with a $0.53 beat.
Despite a strong 2Q print, the mid-to-long term outlook... More
